BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
BIRMINGHAM, Ala., July 17 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced positive results from two Phase 3 studies
of intravenous (i.v.) peramivir in patients with seasonal influenza. The studies
were sponsored by BioCryst's partner Shionogi & Co.,...
PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies
MIDLOTHIAN, Va., June 30 /PRNewswire/ -- In two recent COPD studies
sponsored by DEY LP, PARI's LC Plus nebulizer and PRONEB compressors (Ultra and Ultra II) were used to show that nebulized formoterol fumarate (Perforomist, DEY LP, Mylan Inc.) improves pulmonary function.
"We are pleased th...
School of Dentistry Studies Link Between Oral Health and Memory
MORGANTOWN, W.Va., June 19 /PRNewswire-USNewswire/ -- Keeping your teeth brushed and flossed can cut down on gum disease, drastically reducing risk of heart attack and stroke, dentists have warned for years. Now researchers at West Virginia University have found a clean mouth may also help prese...
Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells
Therapy targets folate receptors found on cancer cells otherwise resistant to standard chemo
ZION, Ill., June 17 /PRNewswire-USNewswire/ -- Cancer Treatment Centers of America (CTCA) at Midwestern Regional Medical Center, a leading provider of innovative cancer care for patients living wi...
New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring
IRVINE, Calif., June 12 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that three new independent studies
demonstrating the clinical accuracy and utility of Masimo PVI as a nonin...
Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
-Second Data Set Presented at MDS-
PARIS, June 9 /PRNewswire/ -- Results from three placebo controlled studies
conducted to assess NT-201 in upper limb post-stroke spasticity, pre-treated cervical dystonia, and treatment-naive cervical dystonia patients represent the second data set presented...
Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery Studies
Advocate Blood Conservation and Appropriate Indicators for Transfusion
IRVINE, Calif., June 8 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that two new studies
Ethicon Endo-Surgery Studies Presented at DDW Demonstrate Potential of Pure NOTES Surgery With Company's Toolbox
CINCINNATI, June 3 /PRNewswire/ -- Ethicon Endo-Surgery, Inc. today announced that multiple studies
presented at the 2009 Digestive Disease Week (DDW) demonstrate the company's novel, investigational* Toolbox enables natural orifice translumenal endoscopic surgery (NOTES) procedures without lap...
Three Independent Studies Include the ImmuKnow(R) Assay to Manage and Optimize Immunosuppression Therapy in Transplant Patients
The results of these studies
will be presented during the American Transplant Congress in Boston, MA May 30 - June 3, 2009
COLUMBIA, Md., May 31 /PRNewswire/ -- A study conducted at Westchester Medical Center in Valhalla, NY examined liver transplant recipients to determine whether the use o...
New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
COLLEGEVILLE, Pa., May 29 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), today announced preliminary data from two ongoing studies, one evaluating neratinib (HKI-272) in combination with trastuzumab (Herceptin(R), Roche) in HER-2 positive (ErbB-2 positive) bre...
VA Studies Advanced Prosthetic Arm
New Mobility for Veterans, Service Members, Other Americans
WASHINGTON, May 27 /PRNewswire-USNewswire/ -- The Department of Veterans Affairs (VA) has announced a three-year study of an advanced artificial arm that easily allows those with severe limb loss to pick up a key or hold a pencil.
PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS
Positive Results Based on New DSCG Formulation & eFlow Technology Delivery
MUNICH and MONTEREY, Calif., May 20 /PRNewswire/ -- This week, Swiss researchers presented positive data from an ongoing Phase II clinical study at the American Thoracic Society (ATS) International Conference that ...
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
- Results suggest pirfenidone may provide meaningful clinical benefit in IPF patients -
- Results of new analyses of efficacy and safety reported -
- Conference Call and Webcast at 9 p.m. EDT (6 p.m. PDT) -
SAN DIEGO, May 19 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN...
Autism Studies Presented at Mid-Atlantic Research Consortium Meeting
PHILADELPHIA, May 8 /PRNewswire-USNewswire/ -- Science is largely a collaborative enterprise. Frequently researchers from various disciplines but with some common interests pool their efforts and exchange ideas, to devise new avenues of investigation. When unraveling complex conditions such as tho...
New Studies Show Popular Heartburn Medications Moderate the Effect of Taking Widely Prescribed Heart Drug
- Four of the most commonly used proton pump inhibitors raise risk of heart attack and stroke for patients taking Plavix(R) and increase healthcare costs
- Drug interaction increases annual hospital costs by nearly 40 percent
FRANKLIN LAKES, N.J., May 6 /PRNewswire-FirstCall/ -- Four ...
New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
Data indicated comparable efficacy and safety for extended release and immediate release formulations of pramipexole
SEATTLE, April 29 /PRNewswire/ -- New findings from two double-blind studies
investigating the efficacy, safety and tolerability of pramipexole dihydrochloride tablets in an ...
Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
- Company will increase focus on HCV pipeline
- Conference call at 8:00 AM ET today
PRINCETON, N.J., April 20 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) announced today that after a discussion with its independent Data Safety Monitoring Board (DSMB) and the FDA, the co...
Alimera Sciences' Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
ATLANTA, April 8 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that an independent Data Safety Monitoring Board (DSMB) has recommended...
Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
Findings Demonstrate Statistically Significant Improvements in Skin Tightening and Tissue Shrinkage;
Data to be Presented at 2009 American Society for Laser Medicine and Surgery Annual Conference
WESTFORD, Mass., April 2 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO ) today an...
Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
SAN DIEGO, March 27 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM ) today reported on an NIH-funded, pre-clinical study conducted by independent researchers at the University of Cincinnati entitled IGF-1--Overexpressing Mesenchymal Stem Cells Accelerate Bone Marrow Stem Cell ...
Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
SAN DIEGO, March 10 /PRNewswire/ -- Avineuro Pharmaceuticals, Inc. announced today an initiation of Phase I clinical studies
of AVN-211, a potent and selective small molecule antagonist of 5-HT6 receptor for treatment of Schizophrenia. The results of Phase I studies
are expected to be available in...
Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
100% Technical Success, No Peri-procedural Complications Reported With Coronary Device
DOYLESTOWN, Pa., March 4 /PRNewswire/ -- Prescient Medical, Inc. reached a crucial milestone in February by completing the enrollment of 30 patients in the first phase of its first-in-human clinical trial f...
Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM) Studies
Support Potential for Alzheimer's Disease and Other Neurodegenerative Diseases
NEW YORK, March 3 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS) , a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheim...
BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
MOUNTAIN VIEW, California, February 23 /PRNewswire/ -- BN
ImmunoTherapeutics, Inc. today provided updated data from its clinical
studies with its breast cancer vaccine, MVA-BN(R)-HER2, in development as
therapy of metastatic breast cancer patients whose tumours over-express HER2.
The study met...
Oridion Announces Significant Medical Studies Presented at STA
JERUSALEM and NEEDHAM, Massachusetts, February 2 /PRNewswire-FirstCall/
-- Oridion Systems Ltd. (SIX Swiss Exchange: ORIDN). During the recent annual
meeting of the Society for Technology in Anesthesia (STA) San Antonio, Texas,
major new findings from numerous medical research projects demonst...
Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
to Investigate Novel Therapy for Ulcerative Colitis and Crohn's Disease
OSAKA, Japan, Jan. 22 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") announced today that its wholly-owned subsidiary, Millennium Pharmaceuticals, Inc., has initiated two Phase III c...
Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed
CAMBRIDGE, Mass. and COLUMBUS, Ohio, Jan. 8 /PRNewswire/ --IntelligentMDx a developer and manufacturer of proprietary nucleic acid assays, today announced that verification studies
of the IntelligentMDx BK Viral Quantitative Assay are complete.
Under the verification protocol the Limit of De...
Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
PARSIPPANY, N.J., Jan. 6 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., an
acute care specialty pharmaceutical company, announced today that enrollment
has been completed in two pivotal Phase III SIMPLE trials to evaluate the
safety and efficacy of a single intraoperative administration of EXPA...
MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
Live Broadcast on December 18, 2008 at 9 a.m. Eastern Time
VALENCIA, Calif., Dec. 15 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD ) will host a live broadcast to review clinical results from its final two Phase 3 studies
of AFRESA(TM), the company's ultra rapid actin...
Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
SAN DIEGO, Dec. 14 /PRNewswire/ -- bioTheranostics, a bioMerieux company
that discovers, develops and commercializes new molecular diagnostic tests in
oncology, reported today findings from three studies
using the company's
molecular breast cancer assay to predict risk of disease recurrence in
Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
Data Showed Campath May Lead to Overall Survival in Patients with Poor Prognostic Factors
SAN FRANCISCO, Dec. 9 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced results from three studies
showing that treatment with Campath(R) (alemtuzumab) showed activity in high-ris...
Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa
NEW ORLEANS, Dec. 8 /PRNewswire/ -- Results published online today in the
New England Journal of Medicine revealed that the world's most clinically
advanced malaria vaccine candidate provides both infants and young children
with significant protection against malaria. Two separate phase II trials
VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
- In Two Studies
Drug was Well-Tolerated, Significantly Inhibited Leukotriene Production, and Reduced Inflammation-
- Webcast Conference Call to Discuss Results on Monday, November 10 at 8:30 a.m. ET-
NEW ORLEANS and SAN FRANCISCO, Nov. 9 /PRNewswire...
Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented
TAMPA, Fla., Nov. 3 /PRNewswire/ -- Sirion Therapeutics, Inc., a
privately held ophthalmic-focused biopharmaceutical company, announced
today that studies
of two investigational drugs in development for
treatment of potentially blinding eye diseases will be presented at
upcoming ophthalmology ...
Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting
IRVINE, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Alsius Corporation
(Nasdaq: ALUS ), the worldwide leader in intravascular temperature
management (IVTM(TM)) therapies, today announced that four scientific
posters featuring both patient cases and laboratory research in which the
Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent
New coronary stent features thin struts designed for more uniform drug delivery
NATICK, Mass., and WASHINGTON, Oct. 12 /PRNewswire-FirstCall/ -- Boston
Scientific Corporation (NYSE: BSX ) today announced comprehensive data from
the TAXUS ATLAS clinical program,...
Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children
Award-winning video clips feature children, parents discussing clinical studies
BETHESDA, Md., Oct. 6 /PRNewswire-USNewswire/ -- From asthma and cancer
treatments to vaccines, research in children saves lives and improves their
health and well-being. A new Web si...
New Studies Highlight Benefits of Coblation(R)-Assisted Procedures in Airway Fire Prevention and Endoscopic Sinus Surgery
Results Presented at the American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting
CHICAGO, Sept. 24 /PRNewswire/ -- In studies
presented this week at the
American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting,
researchers found that Coblat...
New Studies Confirm Safety, Effectiveness of Balloon Sinuplasty(TM) Technology for Chronic Sinusitis
Patients show significant improvement through 2-year follow-up
MENLO PARK, Calif., Sept. 22 /PRNewswire/ -- Two multicenter studies
published this week in Otolaryngology - Head and Neck Surgery confirm
Balloon Sinuplasty(TM) technology is safe and effective when used by
physicians to trea...
Most Cancer Treatment Studies Aren't Published, Study Finds
Concern Raised about 'Cancer Publication Bias'
DURHAM, N.C., Sept. 15 /PRNewswire/ -- Less than 20 percent of
registered clinical trials of cancer treatment are eventually published in
medical journals, according to a study published online today by the
journal "The Oncologist."